CDH1 and non-small cell lung carcinoma: Indeed, we observed in the in vivo co-injection experiments that NSCLC NCI-H292 cells implanted with gMSI2 CAFs, but not with Ctrl CAFs, expressed a high level of the epithelial marker E-cadherin and a low level of the mesenchymal marker vimentin in the primary NSCLC tumor tissues, as evaluated by IHC (Fig. 6A), indicating an impaired EMT in the gMSI2 CAF group.